KGbio is a clinical-stage biotechnology company established in 2016, focused on bringing biologics medical innovation to markets outside the US/Canada, Western Europe and China. The business model revolves around in-licensing novel biologics and select biosimilars in oncology and high-specialty therapeutic areas (typically pre-IND or early clinical stage), with the objective to out-license them in target geographies after finishing clinical development as well as regulatory and reimbursement approvals.
Platforms of interest include Fc-fusion proteins, antibodies, bispecifics, ADCs, cell therapies and therapeutic vaccines. The company is backed by Asian pharma companies Kalbe (market cap US$5.5 billion) and Genexine (market cap US$1.3 billion) and US private equity giant General Atlantic (AUM US$ 78 billion).
KGbio Group Business Model
Chief Executive Officer
Experienced in biopharma corporate strategic investments, marketing, regulatory, and quality. Closely involved with intrapreneurship and organizational development projects
Based in Jakarta
Our Leadership Team
Meet our management team. Our experienced management team is creating a culture of collaboration, excellence, innovation, and accountability that drives our success to bringing biologics medical innovation to the international market.